Integrated endoscopic treatment of primitive unresectable tracheal tumor: the INTACT retrospective cohort study.

Autor: Marchioni A; Respiratory Diseases Unit, University Hospital of Modena, Modena, Italy., Manicardi L; Respiratory Diseases Unit, University Hospital of Modena, Modena, Italy., Tonelli R; Respiratory Diseases Unit, University Hospital of Modena, Modena, Italy.; Clinical and Experimental Medicine PhD Program, University of Modena Reggio Emilia, Modena, Italy., Tabbì L; Respiratory Diseases Unit, University Hospital of Modena, Modena, Italy., Andrisani D; Respiratory Diseases Unit, University Hospital of Modena, Modena, Italy.; Clinical and Experimental Medicine PhD Program, University of Modena Reggio Emilia, Modena, Italy., Lamesta A; Thoracic Surgery Unit, University Hospital of Modena, Modena, Italy., Mocellin A; Respiratory Diseases Unit, University Hospital of Modena, Modena, Italy., Bruzzi G; Respiratory Diseases Unit, University Hospital of Modena, Modena, Italy., Cappiello G; Respiratory Diseases Unit, University Hospital of Modena, Modena, Italy., Andreani A; Pneumology Unit, Santa Maria Bianca Hospital of Mirandola, Modena, Italy., Mattioli F; Othorinolaringoiatry, University Hospital of Modena, Modena, Italy., Filosso P; Thoracic Surgery Unit, University Hospital of Modena, Modena, Italy., Clini E; Respiratory Diseases Unit, University Hospital of Modena, Modena, Italy.
Jazyk: angličtina
Zdroj: Journal of thoracic disease [J Thorac Dis] 2024 May 31; Vol. 16 (5), pp. 2811-2821. Date of Electronic Publication: 2024 May 16.
DOI: 10.21037/jtd-23-738
Abstrakt: Background: Primitive tracheal tumors represent a rare entity whose management, when unresectable, remains challenging. Primary aim of this study was to explore the survival and the factors influencing prognosis of patients with unresectable primitive tracheal tumor undergoing multimodal treatment integrating interventional bronchoscopy and radiotherapy.
Methods: This retrospective cohort study was conducted at the University Hospital of Modena (Italy) over a 12-year period (January 2010 to January 2022) analyzing patients with unresectable primary tracheal tumor receiving interventional bronchoscopy treatment followed by radiotherapy. Survival analysis was conducted for the whole population and according to histology, development of metastasis, stent placement and the onset of disease relapse. The raw and independent association between potential risk factor and 5-year mortality and the reported complications were investigated.
Results: A total of 12 patients were included. Five-year survival rate was 42% with a median survival time of 26.7 (interquartile range, 4.1-82) months. Survivors showed a higher prevalence of cystic-adenoid histology (80% vs. 14%), while patients who were dead at 5 years were those with a more advanced T (prevalence of T2: 71% vs. 0%) and a lower response to first line treatment (57% vs. 0%). Treatment complications accounted for stent dislocation (33%) and the onset of granuloma (18%), while no major side effects were reported. The presence of cystic-adenoid histology resulted in significantly improved 5-year survival rate (80% vs. 14%). The onset of distal metastasis, the occurrence of disease relapse and the placement of tracheal stent did not result significantly associated with lower survival. Among analysed variables, only the presence of cystic-adenoid histology resulted independently associated with survival (odds ratio =0.1, P=0.04).
Conclusions: Multimodal treatment including interventional bronchoscopy and associated radiotherapy for unresectable primary tracheal tumors seems not burdened by significant complications and may provide benefits in terms of survival for those patients with cystic-adenoid histology.
Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-23-738/coif). The authors have no conflicts of interest to declare.
(2024 Journal of Thoracic Disease. All rights reserved.)
Databáze: MEDLINE